Abstract | GU Oncology Now

Abstract

Prognostic and Immunological Role of PPP1R14A as a Pan-Cancer Analysis Candidate

GU Oncology Now EditorsUrothelial Carcinoma | June 3, 2022

Front Genet. 2022 May 17;13:842975. doi: 10.3389/fgene.2022.842975. eCollection 2022. ...

MAP9 Exhibits Protumor Activities and Immune Escape toward Bladder Cancer by Mediating TGF-<em>β</em>1 Pathway

GU Oncology Now EditorsUrothelial Carcinoma | June 3, 2022

J Oncol. 2022 May 24;2022:3778623. doi: 10.1155/2022/3778623. eCollection 2022. ...

Cancer in the Faroe Islands from 1960-2019—Incidence, Mortality, and Comparisons With the Other Nordic Countries

GU Oncology Now EditorsUrothelial Carcinoma | September 13, 2022

In this paper, we present age-standardized cancer incidence and mortality rates in the Faroe Islands.

Insights on recent innovations in bladder cancer immunotherapy

GU Oncology Now EditorsUrothelial Carcinoma | June 3, 2022

Cancer Cytopathol. 2022 Jun 2. doi: 10.1002/cncy.22603. Online ahead of print. ...

Overexpression of long intergenic noncoding RNAs in bladder cancer: A new insight to cancer diagnosis

GU Oncology Now EditorsUrothelial Carcinoma | June 3, 2022

Pathol Res Pract. 2022 May 27;235:153961. doi: 10.1016/j.prp.2022.153961. Online ahead of print. ...

Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study

GU Oncology Now EditorsNon-Muscle Invasive Urothelial Carcinoma | June 3, 2022

Urol Int. 2022 Jun 2:1-7. doi: 10.1159/000524098. Online ahead of print. ...

Rapid SAR optimization for hyperthermic oncology: combining multi-goal optimization and time-multiplexed steering for hotspot suppression

GU Oncology Now EditorsUrothelial Carcinoma | June 3, 2022

Int J Hyperthermia. 2022;39(1):758-771. doi: 10.1080/02656736.2022.2080284. ...

Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma

GU Oncology Now EditorsAdvanced Urothelial Carcinoma | September 26, 2022

Eur Urol. 2022 May 30:S0302-2838(22)02264-3. doi: 10.1016/j.eururo.2022.04.016. Online ahead of print. ...

Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes

GU Oncology Now EditorsNon-Muscle Invasive Urothelial Carcinoma | June 3, 2022

Genome Med. 2022 Jun 3;14(1):59. doi: 10.1186/s13073-022-01056-4. ...

Clinical and Pathological Features of Primary Renal Well-Differentiated Neuroendocrine Tumor

GU Oncology Now EditorsRenal Cell Carcinoma | June 3, 2022

Onco Targets Ther. 2022 May 27;15:587-596. doi: 10.2147/OTT.S364545. eCollection 2022. ...

Comprehensive Pan-Cancer Analysis Reveals the Role of UHRF1-Mediated DNA Methylation and Immune Infiltration in Renal Cell Carcinoma

GU Oncology Now EditorsRenal Cell Carcinoma | June 3, 2022

J Oncol. 2022 May 23;2022:3842547. doi: 10.1155/2022/3842547. eCollection 2022. ...

Clinical Effect of Retroperitoneal Laparoscopic Radical Nephrectomy on Renal Cell Carcinoma, the Influence of Renal Function, and the Influencing Factors of Recurrence

GU Oncology Now EditorsRenal Cell Carcinoma | September 13, 2022

RLRN has been widely used in the surgical treatment of renal cancer due to small wound, less bleeding, and rapid recovery.

Development of a Phagocytosis-Dependent Gene Signature to Predict Prognosis and Response to Checkpoint Inhibition in Clear-Cell Renal Cell Carcinoma

GU Oncology Now EditorsRenal Cell Carcinoma | June 3, 2022

Front Immunol. 2022 May 16;13:853088. doi: 10.3389/fimmu.2022.853088. eCollection 2022. ...

An update on the current epidemiological status of metastatic neoplasms to the thyroid

GU Oncology Now EditorsRenal Cell Carcinoma | June 3, 2022

Cancer Epidemiol. 2022 May 30;79:102192. doi: 10.1016/j.canep.2022.102192. Online ahead of print. ...

Tanshinone IIA exerts autophagic cell death through down-regulation of β-catenin in renal cell carcinoma cells

GU Oncology Now EditorsRenal Cell Carcinoma | June 3, 2022

Biochimie. 2022 May 30:S0300-9084(22)00150-X. doi: 10.1016/j.biochi.2022.05.018. Online ahead of print. ...

Intratumoral resolution of driver gene mutation heterogeneity in renal cancer using deep learning

GU Oncology Now EditorsRenal Cell Carcinoma | June 3, 2022

Cancer Res. 2022 Jun 3:canres.CAN-21-2318-A.2021-7-15 15:52:51.650. doi: 10.1158/0008-5472.CAN-21-2318. Online ahead of ...

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS study

GU Oncology Now EditorsmCSPC | October 12, 2023

Future Oncol. 2022 Jun 3. doi: 10.2217/fon-2022-0433. Online ahead of print. ...

PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications

GU Oncology Now EditorsProstate Cancer | June 3, 2022

Prostate. 2022 Aug;82 Suppl 1:S60-S72. doi: 10.1002/pros.24372. ...

Future Directions for Precision Oncology in Prostate Cancer

GU Oncology Now EditorsRLT | November 15, 2022

Clinical genomic testing is becoming routine in prostate cancer.

Clinical implications of homologous recombination repair mutations in prostate cancer

GU Oncology Now EditorsProstate Cancer | June 3, 2022

Prostate. 2022 Aug;82 Suppl 1:S45-S59. doi: 10.1002/pros.24352. ...